HCM
SLS icon

Highbridge Capital Management’s SELLAS Life Sciences SLS Stock Holding History

Highbridge Capital Management’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,000
Closed -$1.19K – 347
2024
Q2 		$1.19K Buy
+1,000
New +$1.36K ﹤0.01% 326

Other funds holding SLS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCG
Opus Capital Group Cincinnati, Ohio $1.03B AUM 20.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $385M AUM 31.7% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Highbridge Capital Management's SLS Position: Q4 2022 in Review

Highbridge Capital Management sold out of SELLAS Life Sciences (SLS) in Q4 2022, closing a stake of 100,000 shares — an estimated $202K sold.

Highbridge Capital Management first reported a position in SLS in Q2 2022 and held it in 2 quarters. The position peaked at $223K in Q2 2022. 29 funds tracked by Wall St. Rank hold SLS as of Q4 2022.

  • Highbridge Capital Management reported no remaining SELLAS Life Sciences position as of Q4 2022 after selling out during the quarter.
  • Highbridge Capital Management sold 100,000 SELLAS Life Sciences shares in Q4 2022, an estimated $202K.
  • Highbridge Capital Management first reported a position in SELLAS Life Sciences in Q2 2022 and held it in 2 quarters.
  • Highbridge Capital Management's SELLAS Life Sciences position peaked at $223K in Q2 2022.
  • 29 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q4 2022.

Based on Highbridge Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.